GO
Loading...

Enter multiple symbols separated by commas

Search results for "WPI"

REFINE RESULTS

SEARCH RESULTS

About 17 results. Sort By: Date | Relevance
US appeals court upholds delay in Alzheimer's drug swap

ALBANY, N.Y.- A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer. He alleged anti-trust and state law violations by Actavis in an effort to push patients to its new patented drug and avoid losses from...
Source: The Associated Press
UPDATE 1-Actavis cannot drop old version of Alzheimer's drug -appeals court

NEW YORK, May 22- Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court in New York ruled on Friday. The decision at the 2nd U.S. Circuit Court of Appeals is a win for New York State Attorney General Eric Schneiderman, who sued to block the switch, arguing that Actavis was...
Source: Reuters | By: Joseph Ax and Brendan Pierson
Actavis cannot drop old version of Alzheimer's drug - appeals court

NEW YORK, May 22- Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court ruled on Friday. A three-judge panel at the 2nd U.S. Circuit Court of Appeals in New York upheld an order by U.S. District Robert Sweet in December requiring Actavis to keep the older drug, Namenda IR, on the...
Source: Reuters
Actavis says Warner Chilcott unit held talks to settle U.S. probe

May 14- Drug maker Actavis Plc said its Warner Chilcott unit held talks with U.S. government officials to discuss a potential resolution of an investigation into the unit's sales activities, according to a regulatory filing. Warner Chilcott said the company and several of its employees in the sales organization received subpoenas in 2012 from the United...
Source: Reuters
Noble Energy and Zulily are big market movers

NEW YORK- Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Noble Energy Inc., down $3.05 to $46.07. The energy company will pay about $2.1 billion for Rosetta Resources in a deal that will give it access to two Texas shale formations.
Source: The Associated Press
UPDATE 2-Actavis expects Allergan business to drive 2015 growth

*Actavis initial forecast historically conservative- analysts. Sales of Allergan products for 15 days and the drugs acquired with the Forest Laboratories deal helped Actavis beat revenue estimate in the quarter ended March 31. Actavis, whose shares were up 3 percent, outbid Canadian drugmaker Valeant Pharmaceuticals International Inc and activist...
Source: Reuters | By: Vidya L Nathan
US STOCKS-Wall St mixed at open; energy shares fall

*Rosetta soars as Noble Energy offers to buy company for $2 bln. *Zulily rises after Alibaba increases stake. Exxon Mobil shares fell 1.1 percent to $87.28.
Source: Reuters | By: Tanya Agrawal
Asian stocks retreat as Greek cash crunch intensifies

Exxon Mobil lost 1.7 percent, the most in the Dow Jones industrial average. Benchmark U.S. crude fell 14 cents to close at $59.25 a barrel in New York. "It's a day of digestion after big news and a big move on Friday," said Eric Wiegand, a senior portfolio manager at U.S.
Source: The Associated Press | By: By ALEX VEIGA, AP Business Writer
Stocks barely budge in early trade following big gain Friday

NEW YORK- Stocks are barely budging in early trading as the market comes off its biggest gain in two months. Dean Foods jumped 10 percent early Monday after the company reported earnings that beat analysts' forecasts. Actavis also rose after its results beat estimates.
Source: The Associated Press
US STOCKS-Futures little changed after soaring last week on strong jobs data

*Rosetta soars as Noble Energy offers to buy company for $2 bln. *Zulily rises after Alibaba increases stake. "There will be some carry-over from the positive jobs report but not at the same magnitude," said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.
Source: Reuters | By: Tanya Agrawal